SERA vs. CDNA, BDSX, CSTL, CELC, LUCD, CODX, FLGT, TLIS, VRDN, and VMD
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include CareDx (CDNA), Biodesix (BDSX), Castle Biosciences (CSTL), Celcuity (CELC), Lucid Diagnostics (LUCD), Co-Diagnostics (CODX), Fulgent Genetics (FLGT), Talis Biomedical (TLIS), Viridian Therapeutics (VRDN), and Viemed Healthcare (VMD). These companies are all part of the "medical" sector.
Sera Prognostics (NASDAQ:SERA) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, community ranking, valuation, earnings, analyst recommendations and media sentiment.
54.6% of Sera Prognostics shares are held by institutional investors. 15.6% of Sera Prognostics shares are held by insiders. Comparatively, 4.2% of CareDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Sera Prognostics currently has a consensus price target of $2.75, indicating a potential downside of 73.40%. CareDx has a consensus price target of $13.50, indicating a potential upside of 78.57%. Given CareDx's higher probable upside, analysts clearly believe CareDx is more favorable than Sera Prognostics.
CareDx has a net margin of -67.88% compared to Sera Prognostics' net margin of -11,843.79%. Sera Prognostics' return on equity of -45.74% beat CareDx's return on equity.
In the previous week, CareDx had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for CareDx and 1 mentions for Sera Prognostics. CareDx's average media sentiment score of 0.79 beat Sera Prognostics' score of 0.00 indicating that CareDx is being referred to more favorably in the news media.
Sera Prognostics has higher earnings, but lower revenue than CareDx. Sera Prognostics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
CareDx received 413 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 66.56% of users gave CareDx an outperform vote while only 36.00% of users gave Sera Prognostics an outperform vote.
Sera Prognostics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, CareDx has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
Summary
CareDx beats Sera Prognostics on 9 of the 17 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
